BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32966986)

  • 1. Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study.
    Miyoshi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C
    Oncology; 2021; 99(2):105-113. PubMed ID: 32966986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of preventive effects of combined furosemide and mannitol versus single diuretics, furosemide or mannitol, on cisplatin-induced nephrotoxicity.
    Takagi A; Miyoshi T; Hayashi T; Koizumi H; Tsumagari K; Yokota C; Nakano T; Matsuo K; Egawa T
    Sci Rep; 2024 May; 14(1):10511. PubMed ID: 38714773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk Factors Associated with Cisplatin-Induced Nephrotoxicity in Patients with Advanced Lung Cancer.
    Miyoshi T; Misumi N; Hiraike M; Mihara Y; Nishino T; Tsuruta M; Kawamata Y; Hiraki Y; Kozono A; Ichiki M
    Biol Pharm Bull; 2016; 39(12):2009-2014. PubMed ID: 27904042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventive effect of 20 mEq and 8 mEq magnesium supplementation on cisplatin-induced nephrotoxicity: a propensity score-matched analysis.
    Miyoshi T; Hayashi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C; Nakano T; Egawa T
    Support Care Cancer; 2022 Apr; 30(4):3345-3351. PubMed ID: 34984552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection.
    Kidera Y; Kawakami H; Sakiyama T; Okamoto K; Tanaka K; Takeda M; Kaneda H; Nishina S; Tsurutani J; Fujiwara K; Nomura M; Yamazoe Y; Chiba Y; Nishida S; Tamura T; Nakagawa K
    PLoS One; 2014; 9(7):e101902. PubMed ID: 25020203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.
    Ikemura K; Oshima K; Enokiya T; Okamoto A; Oda H; Mizuno T; Ishinaga H; Muraki Y; Iwamoto T; Takeuchi K; Katayama N; Okuda M
    Cancer Chemother Pharmacol; 2017 May; 79(5):943-949. PubMed ID: 28364288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study.
    Yoshida T; Niho S; Toda M; Goto K; Yoh K; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y
    Jpn J Clin Oncol; 2014 Apr; 44(4):346-54. PubMed ID: 24503028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrolytes supplementation can decrease the risk of nephrotoxicity in patients with solid tumors undergoing chemotherapy with cisplatin.
    Minzi OMS; Lyimo TE; Furia FF; Marealle AI; Kilonzi M; Bwire GM; Malichewe C
    BMC Pharmacol Toxicol; 2020 Sep; 21(1):69. PubMed ID: 32967726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
    Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
    Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between magnesium pre-loading and cisplatin-induced nephrotoxicity in 5-fluorouracil/cisplatin combination therapy for esophageal cancer.
    Sugisaki T; Aoyama T; Kawakami K; Yokokawa T; Kobayashi K; Suzuki W; Ogura M; Ichimura T; Chin K; Yamaguchi K; Hanaoka S; Hayashi H; Yamaguchi M
    Pharmazie; 2022 Feb; 77(2):85-88. PubMed ID: 35209969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telmisartan Exacerbates Cisplatin-Induced Nephrotoxicity in a Mouse Model.
    Hosoda A; Matsumoto Y; Toriyama Y; Tsuji T; Yoshida Y; Masamichi S; Kohno T
    Biol Pharm Bull; 2020; 43(9):1331-1337. PubMed ID: 32879207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin pharmacokinetics and its nephrotoxicity in diabetic rabbits.
    Najjar TA; Saad SY
    Chemotherapy; 2001; 47(2):128-35. PubMed ID: 11173815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
    Nagai N; Kinoshita M; Ogata H; Tsujino D; Wada Y; Someya K; Ohno T; Masuhara K; Tanaka Y; Kato K; Nagai H; Yokoyama A; Kurita Y
    Cancer Chemother Pharmacol; 1996; 39(1-2):131-7. PubMed ID: 8995510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study.
    Komaki K; Kusaba T; Tanaka M; Kado H; Shiotsu Y; Matsui M; Shiozaki A; Nakano H; Ishikawa T; Fujiwara H; Konishi H; Itoh Y; Matoba S; Tamagaki K
    BMC Cancer; 2017 Feb; 17(1):144. PubMed ID: 28219368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective evaluation of furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity.
    Mach CM; Kha C; Nguyen D; Shumway J; Meaders KM; Ludwig M; Williams-Brown MY; Anderson ML
    J Clin Pharm Ther; 2017 Jun; 42(3):286-291. PubMed ID: 28276070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kidney-protective Effect of Magnesium Supplementation in Cisplatin-containing Chemotherapy for Pediatric Cancer: A Retrospective Study.
    Matsui M; Saito Y; Yamaoka S; Yokokawa Y; Morikawa Y; Makimoto A; Yuza Y
    J Pediatr Hematol Oncol; 2018 Jul; 40(5):379-381. PubMed ID: 29683958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnesium co-administration decreases cisplatin-induced nephrotoxicity in the multiple cisplatin administration.
    Saito Y; Okamoto K; Kobayashi M; Narumi K; Furugen A; Yamada T; Iseki K
    Life Sci; 2017 Nov; 189():18-22. PubMed ID: 28864226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic protective effect of
    Abdel-Wahab WM; Moussa FI; Saad NA
    Drug Des Devel Ther; 2017; 11():901-908. PubMed ID: 28356716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the rates of cisplatin (cDDP)--induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure.
    Leu L; Baribeault D
    J Oncol Pharm Pract; 2010 Sep; 16(3):167-71. PubMed ID: 19759050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of cisplatin-induced nephrotoxicity between single-dose and split-dose administration to rats.
    Fukushima K; Futatsugi A; Maekawa M; Naito S; Okada A; Sugioka N
    Biomed Pharmacother; 2022 Mar; 147():112619. PubMed ID: 34999374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.